Clinical trials: Thromboprophylaxis
Acute Deep Vein Thrombosis
Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients
To collect postmarketing data about Fragmin safety and efficacy in the treatment of deep vein thrombosis with or without pulmonary embolism in cancer patients.
- Trial name
- NCT00480636
- Testing
- Fragmin (dalteparin sodium )
- Volunteers
- 102 people
- Sponsor
- Pfizer
Blood Clot, Trauma
PREVENTion of Clot in Orthopaedic Trauma
The purpose of this study is to compare aspirin versus low-molecular weight heparin (LMWH) (Enoxaparin) as a thromboprophylaxis in patients who sustain a fracture.
- Trial name
- PREVENT CLOT (NCT02984384)
- Testing
- Acetylsalicylic acid, Low Molecular Weight Heparin (LMWH)
- Where
- 21 sites in United States, Canada
- Volunteers
- 12,424 people
- Sponsor
- Major Extremity Trauma Research Consortium
Ovarian Cancer
Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)
This research study is studying a combination of two drug interventions called rosuvastatin and enoxaparin as a possible preventative measure against developing venous blood clots (such deep vein thrombosis or pulmonary…
- Trial name
- NCT03532139
- Testing
- Enoxaparin, Enoxaparin + Rosuvastatin, Thromboprophylaxis
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Beth Israel Deaconess Medical Center
Thrombophilia
A Comparison of Sequential Compression Devices and Foot Pumps in the Obstetric Population
The researchers at Johns Hopkins University believe that the foot pump will be superior to sequential compression devices in comfort and patient compliance which may increase provider efforts to prevent deep vein thrombosis (DVT)…
- Trial name
- NCT00356434
- Testing
- Kendall A-V foot impulse pump, model 6060, Kendall sequential compression device, model 9525
- Where
- 2 sites in United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Thromboembolic Complications
Thrombelastography Based Dosing of Enoxaparin
The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox®) is given to patients who are at a higher risk of developing clots in their legs or lungs.
- Trial name
- NCT00990236
- Testing
- Enoxaparin dose adjusted Lovenox based on TEG, Enoxaparin 30 mg BID
- Where
- 3 sites in United States
- Volunteers
- 185 people
- Sponsor
- Oregon Health and Science University
Pancreatic Cancer, Venous Thromboembolism
Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
The goal of this clinical research study is to learn if dalteparin can lower the risk of VTE occurring in the legs and lungs. This will be tested in patients with pancreatic cancer who are going to receive chemotherapy.
- Trial name
- NCT00966277
- Testing
- Dalteparin
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- M.D. Anderson Cancer Center
Venous Thromboembolism
Toronto Thromboprophylaxis Patient Safety Initiative
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE, is one of the common and preventable complications of hospital stay.
- Trial name
- TOPPS (NCT01869075)
- Testing
- Knowledge Translation (KT) toolkit
- Where
- Canada
- Volunteers
- 1,895 people
- Sponsor
- Sunnybrook Health Sciences Centre
Gynecologic Cancer, Venous Thromboembolism
Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
The study will evaluate the incidence of major bleeding (including clinically relevant non-major (CRNM) bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg twice a day (BID) compared to…
- Trial name
- NCT02366871
- Testing
- Oral apixaban, Subcutaneous enoxaparin
- Where
- 2 sites in United States
- Volunteers
- 400 people
- Sponsor
- University of Colorado, Denver
Advanced Pancreatic, Colon, Lung, Gastric and Ovarian Cancer
Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
Research studies have shown a strong association between cancer and blood clots in the veins (also known as deep vein thrombosis).
- Trial name
- MicroTEC (NCT00908960)
- Testing
- Enoxaparin
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Beth Israel Deaconess Medical Center
Atrial Fibrillation, Atrial Flutter
Impact of an Atrial Fibrillation Decision Support Tool (AFDST) on Thromboprophylaxis for Atrial Fibrillation
Study objective was to improve decision-making and thromboprophylaxis for patients with Atrial Fibrillation (AF) by developing and implementing a computerized decision support tool for individual patient-level decision-making…
- Trial name
- NCT02524977
- Testing
- Decision Support, Educational Intervention Only
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
Pulmonary Embolism, Thoracic Surgery
Chemoprophylaxis Plus Early Ambulation
Pulmonary embolism (PE) can be a devastating postoperative complication and the leading cause of mortality after thoracic surgery.
- Trial name
- NCT03862755
- Testing
- Chemoprophylaxis with Low Molecular Weight Heparin (LMWH)
- Where
- China
- Volunteers
- 581 people
- Sponsor
- Shen Lei
Obesity, Obesity, Morbid
Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis
Pregnant and recently postpartum women are at significantly higher risk of developing a blood clot in their arms or legs known as a deep venous thrombosis (DVT) and/or a blood clot in their lungs known as a pulmonary embolism…
- Conditions
- Obesity, Obesity, Morbid, Pregnancy, Complications; Cesarean Section
- Trial name
- NCT02070237
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- MemorialCare Health System
Hip Fracture, Myocardial Ischemia
Pilot Study of Atorvastatin for Orthopedic Surgery Patients
Up to 35% of hip fracture patients have been shown to experience heart injury after surgery, and as many as 10% have a heart attack or die in the three months after surgery.
- Conditions
- Hip Fracture, Myocardial Ischemia, Inflammation
- Trial name
- POST-OP Pilot (NCT02197065)
- Testing
- Atorvastatin
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Hospital for Special Surgery, New York
Thrombosis, Venous
Hemorrhage Risk Prescribed Arixtra
Arixtra (fondaparinux sodium) was the first selective Factor Xa inhibitor to be marketed. As with all anticoagulants, an important adverse event associated with Arixtra use is haemorrhage.
- Trial name
- NCT01064362
- Testing
- Fondaparinux sodium, Low molecular weight heparin (LMWH)
- Volunteers
- 13,442 people
- Sponsor
- GlaxoSmithKline
Venous Thromboembolism, Arthroplasty
Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty
Venous thromboembolism is a serious complication after total hip replacement (THR) and total knee replacement (TKR). Previous studies have reported the incidence of both asymptomatic and symptomatic deep vein thrombosis (DVT)…
- Trial name
- NCT05449327
- Testing
- Rivaroxaban 10 MG
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- Chiayi Christian Hospital
Pregnancy Related, Antepartum DVT
Heparin Prophylaxis Dosing for Antepartum Hospitalizations (HEPDOSE)
This study is a randomized control trial to compare gestational age-based dosing with standard dosing of unfractionated heparin for thromboprophylaxis of hospitalized antepartum patients.
- Trial name
- NCT04635839
- Testing
- Standard Dose of Unfractionated Heparin, Gestational Age-Based Dose of Unfractionated Heparin
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Covid19
COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis
A multicenter, adaptive, randomized platform trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge
- Trial name
- NCT04650087
- Testing
- Apixaban 2.5 MG
- Where
- 121 sites in United States
- Volunteers
- 1,291 people
- Sponsor
- Thomas L. Ortel
Thrombosis
Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure
The Purpose of this study is to characterize the single and multiple-dose pharmacokinetic (PK) and pharmacokinetic/pharmacodynamic (PK/ PD) profiles after oral rivaroxaban therapy administered to pediatric participants 2 to 8…
- Trial name
- UNIVERSE (NCT02846532)
- Testing
- Rivaroxaban, Acetylsalicylic Acid
- Where
- 42 sites in United States, Argentina and 8 more
- Volunteers
- 112 people
- Sponsor
- Janssen Research & Development, LLC
Pulmonary Embolism, Deep Vein Thrombosis
Angel® Catheter Early Feasibility Clinical Study
The primary objective of this clinical trial is to obtain initial insights into the safety of the Angel® Catheter in critically ill subjects with high risk of venous thromboembolism (VTE) disease AND who are not receiving…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
- Trial name
- NCT01847196
- Testing
- Angel® Catheter
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- BiO2 Medical
Upper Extremity Deep Vein Thrombosis, Central Venous Catheter Thrombosis
Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines
Purpose of the Pilot Trial: To determine the feasibility of conducting a multicentre randomized open label controlled trial evaluating the use of prophylactic dose rivaroxaban to prevent central venous catheter (CVC) associated…
- Conditions
- Upper Extremity Deep Vein Thrombosis, Central Venous Catheter Thrombosis, Cancer
- Trial name
- TRIM-Line (NCT03506815)
- Testing
- Rivaroxaban 10 MG
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- Ottawa Hospital Research Institute